Why You Should Add Agilent (A) To Your Portfolio Right Now
Zacks Investment Research | Oct 10, 2017 09:38PM ET
Agilent Technologies ( (NYSE:A) ) is an original equipment manufacturer (OEM) of a broad portfolio of test and measurement products serving multiple end markets. The company’s portfolio and increased focus on segments with higher growth potential is a big positive. The company also enjoys a robust presence in the health care market.
A few recent developments bode well for the company’s growth.
One such development is the FDA’s approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx. The test will be used in cases of urothelial carcinoma (“UC”) and squamous cell carcinoma of the head and neck (“SCCHN”).
The PDL1 IHC 28-8 pharmDx test has already been approved for melanoma as well as non-squamous, non-small-cell lung cancer (“NSCLC”). It has now been approved for UC and SCCHN patients too. The test enables physicians in the United States to identify UC and SCCHN patients, who still have disease progression on or after platinum-based chemotherapy and are most likely to benefit from treatment with Opdivo.
We are encouraged by the company’s efforts to develop new assays for cancer treatment.The new assay will help Agilent to cash in on the fast-growing health care cancer-diagnostics segment.
Also, Agilent has an impressive record of returning cash to its shareholders through share buybacks and regular dividend payouts. In the fiscal third quarter, Agilent did not repurchase any share but paid out $42 million as dividends.
Moreover, the recently acquired Cobalt Light Systems will allow Agilent to strengthen its presence in the high-growth Raman spectroscopy market. The deal complements Agilent’s own product expansion efforts, with a promise to offer better services to its pharmaceutical and biopharma customers.
An Outperformer
A look at the company’s price trend reveals that the stock has had an impressive run on the bourse year to date. Agilent has gained 46.2%, significantly outperforming the industry ’s gain of 43.7%.
Northward Estimate Revisions
For the current fiscal year 2017, 10 estimates have moved north over the past 60 days against no southward revisions, reflecting analysts’ confidence in the company. Over the same period, the Zacks Consensus Estimate for the current year has increased 4.5%.
Strong Growth Prospects
The company’s Zacks Consensus Estimate for fiscal 2017 earnings of $2.32 reflects year-over-year growth of 17.02%. Moreover, earnings are expected to register 11.83% growth in 2018. The stock has long-term expected earnings per share growth rate of 9.8%.
Get The News You Want
Agilent Technologies, Inc. Price and Consensus
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.